Held on October 15th, the Group’s annual meeting brought together representatives of the Group’s member hospitals, particularly those sitting on its Board of Directors, Scientific Committee or Operations Committee.
This meeting was an opportunity for the Group’s founding couple to highlight the leadership of the administrators, the expertise of the researchers of the Scientific Committee chaired by Dr. Asselah, as well as the mobilization of the research coordinators and the support from the Group’s member hospitals’ teams.
Mr. Sirois also highlighted the support of several of the Group’s partners, including Breast Cancer Canada, supports the Programme Accès-recherche Dr André-Robidoux, bringing research closer to patients outside major urban centers. He also recognized the Canadian Cancer Society, Fondation cancer du sein du Québec, Pfizer, AstraZeneca, Gilead, Novartis, Merck, Lilly and Seagen for their support of the first Quebec metastatic breast cancer registry launched by the Group in 2021.
Ms. McPeak recalled the importance of the work carried out together by the 12-member hospital centers joining forces to increase access and participation in research that cares across the province.
